Segev A - Search Results

1

Thr325Ile polymorphism of the TAFI gene is related to TAFI antigen plasma levels and angiographic restenosis after percutaneous coronary interventions.

Segev A, Hegele RA, Lau HK, Sparkes JD, Teitel JM, Chisholm RJ, Strauss BH. Segev A, et al. Thromb Res. 2004;114(2):137-41. doi: 10.1016/j.thromres.2004.06.003. Thromb Res. 2004. PMID: 15306156 Clinical Trial.

2

Collagenase plaque digestion for facilitating guide wire crossing in chronic total occlusions.

Strauss BH, Goldman L, Qiang B, Nili N, Segev A, Butany J, Sparkes JD, Jackson ZS, Eskandarian MR, Virmani R. Strauss BH, et al. Among authors: segev a. Circulation. 2003 Sep 9;108(10):1259-62. doi: 10.1161/01.CIR.0000086320.24172.A1. Epub 2003 Aug 25. Circulation. 2003. PMID: 12939226

3

Endocardial cryotherapy as a novel strategy of improving myocardial perfusion in a patient with severe coronary artery disease.

Segev A, Strauss BH, Coates G, Freeman MR, Gallo R. Segev A, et al. Catheter Cardiovasc Interv. 2003 Oct;60(2):229-32. doi: 10.1002/ccd.10621. Catheter Cardiovasc Interv. 2003. PMID: 14517931

4

Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis.

Lau HK, Segev A, Hegele RA, Sparkes JD, Teitel JM, Chisholm RJ, Strauss BH. Lau HK, et al. Among authors: segev a. Thromb Haemost. 2003 Dec;90(6):1187-91. doi: 10.1160/TH03-05-0308. Thromb Haemost. 2003. PMID: 14652655

5

Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.

Tsimikas S, Lau HK, Han KR, Shortal B, Miller ER, Segev A, Curtiss LK, Witztum JL, Strauss BH. Tsimikas S, et al. Among authors: segev a. Circulation. 2004 Jun 29;109(25):3164-70. doi: 10.1161/01.CIR.0000130844.01174.55. Epub 2004 Jun 7. Circulation. 2004. PMID: 15184281

6

Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting.

Segev A, Kassam S, Buller CE, Lau HK, Sparkes JD, Connelly PW, Seidelin PH, Natarajan MK, Cohen EA, Strauss BH. Segev A, et al. Eur Heart J. 2004 Jun;25(12):1029-35. doi: 10.1016/j.ehj.2004.04.027. Eur Heart J. 2004. PMID: 15191773

7

Low rates of angiographic and clinical restenosis with the new flexible MedStent for the treatment of single discrete coronary lesions.

Segev A, Cantor WJ, Cohen EA, Seidelin PH, Natarajan MK, Marquis JF, Lazzam C, Watson RK, Chisholm RJ, Strauss BH. Segev A, et al. J Interv Cardiol. 2004 Jun;17(3):167-70. doi: 10.1111/j.1540-8183.2004.09881.x. J Interv Cardiol. 2004. PMID: 15209579 Clinical Trial.

8

The role of perlecan in arterial injury and angiogenesis.

Segev A, Nili N, Strauss BH. Segev A, et al. Cardiovasc Res. 2004 Sep 1;63(4):603-10. doi: 10.1016/j.cardiores.2004.03.028. Cardiovasc Res. 2004. PMID: 15306215 Review.

9

Poly(methylidene malonate 2.1.2) nanoparticles: a biocompatible polymer that enhances peri-adventitial adenoviral gene delivery.

Qiang B, Segev A, Beliard I, Nili N, Strauss BH, Sefton MV. Qiang B, et al. Among authors: segev a. J Control Release. 2004 Aug 27;98(3):447-55. doi: 10.1016/j.jconrel.2004.05.017. J Control Release. 2004. PMID: 15313000

10

Postprocedural low molecular weight heparin in patients at high risk of subacute stent thrombosis.

Daoulah A, Segev A, Leblanc K, Chisholm RJ, Strauss BH. Daoulah A, et al. Among authors: segev a. Cardiovasc Radiat Med. 2003 Oct-Dec;4(4):182-5. doi: 10.1016/j.carrad.2004.02.001. Cardiovasc Radiat Med. 2003. PMID: 15321055

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

308 results

Search Page

Filters